Stock Price
504.80
Daily Change
-5.40 -1.06%
Monthly
8.12%
Yearly
-12.06%
Q4 Forecast
489.05



Peers Price Chg Day Year Date
Ambu A/S 90.50 -0.80 -0.88% 6.97% Nov/17
Brookdale Senior Living 8.96 -0.21 -2.29% -14.59% Nov/16
Coloplast 504.80 -5.40 -1.06% -12.06% Nov/17
Cencora 356.94 -2.09 -0.58% -2.21% Nov/16
Encompass Health 142.11 1.12 0.79% 26.88% Nov/16
Enovis 27.92 0.24 0.87% -1.34% Nov/16
GE HealthCare Technologies 82.96 -0.06 -0.07% 17.46% Nov/16
Pediatrix Medical Group 31.89 0.59 1.89% 48.53% Nov/16
Veradigm 5.18 0.18 3.60% 9.05% Nov/16
OPKO Health 535.00 -6.60 -1.22% 29.92% Nov/16

Indexes Price Day Year Date
Copenhagen 1675 -11.17 -0.66% 12.59% Nov/17

Coloplast traded at 504.80 this Tuesday November 17th, decreasing 5.40 or 1.06 percent since the previous trading session. Looking back, over the last four weeks, Coloplast lost 8.12 percent. Over the last 12 months, its price fell by 12.06 percent. Looking ahead, we forecast Coloplast to be priced at 489.05 by the end of this quarter and at 436.34 in one year, according to Trading Economics global macro models projections and analysts expectations.

Coloplast A/S is a Denmark-based company active within the healthcare sector. It is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The Company supplies products to hospitals, institutions as well as wholesalers and pharmacies.